CD83 is a new potential biomarker and therapeutic target for Hodgkin lymphoma.

about

CD83 in Hodgkin lymphoma.

P2860

Q55040297-0B80C162-84A2-491B-AD9C-5AABB3F28DFD

P2860

CD83 is a new potential biomarker and therapeutic target for Hodgkin lymphoma.

Item

http://www.wikidata.org/entity/Q49912584

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

CD83 is a new potential biomarker and therapeutic target for Hodgkin lymphoma.

@en

CD83 is a new potential biomarker and therapeutic target for Hodgkin lymphoma.

@nl

type

Item

label

CD83 is a new potential biomarker and therapeutic target for Hodgkin lymphoma.

@en

CD83 is a new potential biomarker and therapeutic target for Hodgkin lymphoma.

@nl

prefLabel

CD83 is a new potential biomarker and therapeutic target for Hodgkin lymphoma.

@en

CD83 is a new potential biomarker and therapeutic target for Hodgkin lymphoma.

@nl

P1476

CD83 is a new potential biomarker and therapeutic target for Hodgkin lymphoma

@en

P2093

Annemarie Hennessy

http://www.w3.org/2001/XMLSchema#string

Candice Clarke

http://www.w3.org/2001/XMLSchema#string

Christian E Bryant

http://www.w3.org/2001/XMLSchema#string

Christina Brown

http://www.w3.org/2001/XMLSchema#string

Con Tsonis

http://www.w3.org/2001/XMLSchema#string

Derek N J Hart

http://www.w3.org/2001/XMLSchema#string

Edward Abadir

http://www.w3.org/2001/XMLSchema#string

Fiona Kupresanin

http://www.w3.org/2001/XMLSchema#string

Geoffrey A Pietersz

http://www.w3.org/2001/XMLSchema#string

Ilona Cunningham

http://www.w3.org/2001/XMLSchema#string

P2860

CD83 is preformed inside monocytes, macrophages and dendritic cells, but it is only stably expressed on activated dendritic cells

Latent membrane protein 1 of Epstein-Barr virus induces CD83 by the NF-kappaB signaling pathway

The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints

Systematic review and meta-analysis on the prognostic value of complete remission status at FDG-PET in Hodgkin lymphoma after completion of first-line therapy

Brentuximab vedotin

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

Efficient construction of a large nonimmune phage antibody library: the production of high-affinity human single-chain antibodies to protein antigens

CD83 modulates B cell function in vitro: increased IL-10 and reduced Ig secretion by CD83Tg B cells.

A method for rapid, ligation-independent reformatting of recombinant monoclonal antibodies.

Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.

P304

655-665

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3324/HAEMATOL.2017.178384

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

103

http://www.w3.org/2001/XMLSchema#string

P50

P577

2018-01-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29351987

http://www.w3.org/2001/XMLSchema#string

P932

5865416

http://www.w3.org/2001/XMLSchema#string

CD83 is a new potential biomarker and therapeutic target for Hodgkin lymphoma.

about

P2860

P2860

CD83 is a new potential biomarker and therapeutic target for Hodgkin lymphoma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932